Results 271 to 280 of about 38,022 (310)

Delivery Device Patents on GLP-1 Receptor Agonists

JAMA
This study analyzed the US Food and Drug Administration–listed patents on glucagon-like peptide 1 (GLP-1) receptor agonists to determine their claim characteristics and the potential barriers they pose to generic entry.
Rasha, Alhiary, Sarah, Gabriele, Aaron S, Kesselheim, S Sean, Tu, William B, Feldman   +4 more
openaire   +2 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes

The Medical Letter on Drugs and Therapeutics
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 ...
openaire   +2 more sources

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

GLP-1 receptor agonists and suicidality

BMJ
Peter, Ueda, Björn, Pasternak
openaire   +2 more sources

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly